Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy of Desvenlafaxine SR in MDD
NCT01432457Phase 4Completed
- Sponsor
- Pfizer
- Start
- Oct 2011
- Primary completion
- Jul 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of desvenlafaxine in major depressive disorder (MDD) (3 arms), sponsored by Pfizer. Primary endpoint: Hamilton Rating Scale for Depression, 17-item Total Score at 8 weeks. Started Oct 2011; status: completed.
02
Drugs
desvenlafaxine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT01432457.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01432457.